TCL Archive Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment. July 30, 2004
TCL Archive ASH Highlights: Improved Treatments For NHL, Poor Prognostic Factors For B-Cell In Children January 30, 2004
